Childhood asthma: exhaled nitric oxide in relation to clinical symptoms

A. Artlich*, T. Busch*, K. Lewandowski†, S. Jonas*, L. Gortner*, K.J. Falke†

ABSTRACT: Bronchial asthma is associated with increased levels of exhaled nitric oxide which are suppressible by glucocorticosteroid inhalation. Children with bronchial asthma were studied to elucidate the relation between endogenous NO release and recent symptoms of bronchial obstruction.

Twenty-five children with atopic asthma and 11 healthy control subjects were enrolled and exhaled NO was studied using chemiluminescence analysis. The subjects breathed purified air (<0.5 parts per billion (ppb) NO) exclusively through their mouths. Orally expired NO was measured during continuous nasal aspiration (1.3 L·min⁻¹) to remove nasally produced NO. Nasal NO concentration was determined within the aspirated gas.

Orally expired NO concentration was 2.5±0.3 ppb (mean±SEM) in healthy control subjects, 3.19±0.86 ppb (ns) in symptom-free children, and 8.28±0.81 ppb (p<0.01) in children with bronchial asthma who had had recent symptoms of bronchial obstruction. Similarly, in the subgroup of children treated regularly with inhaled glucocorticosteroids those with recent symptoms had significantly higher orally exhaled NO concentrations than healthy control subjects (9.5±1.5 ppb, p<0.05). The nasal NO concentration was 152.8±12.7 ppb in healthy control subjects and not significantly different in asthmatic children.

In this group of asthmatic children, recent symptoms of bronchial obstruction were linked to significantly higher concentrations of NO in orally exhaled gas and to increased oral NO excretion rates. If substantiated by further studies, measurement of orally exhaled NO during nasal aspiration may become useful to monitor disease control in asthmatic children.


Nitric oxide can be detected in exhaled gas of various mammals including humans [1] and is increased in patients with bronchial asthma [2–8]. In adults, the increase is mainly due to increased production in the lower airways [9, 10] although at present it is not clear whether the increased exhaled NO in asthmatics reflects a beneficial response counterbalancing bronchoconstrictor stimuli or contributes to increased tissue damage and perpetuation of immune responses [11, 12]. There is sufficient evidence to conclude that NO synthesis is induced by the underlying chronic inflammatory process in bronchial asthma: in vitro studies have shown the inducibility of NO synthesis by inflammatory cytokines relevant to asthma [13, 14]. Inducible NO synthase (iNOS) has been detected immunohistochemically in bronchial epithelial cells of asthmatic patients [13] and in alveolar macrophages from areas of chronic inflammation [15]. The inhalation of a pulmonary irritant has been shown to enhance NO production by alveolar macrophages in rats [16]. Furthermore, antigen-induced bronchoconstriction specifically affects exhaled NO levels and is antagonized by endogenous NO in animal studies [17, 18]. Treatment with glucocorticosteroids reduces the expression of iNOS in macrophages in vitro [19] and leads to a decrease of exhaled NO levels in adults and children with asthma [8, 20, 21].

The major part of exhaled NO normally derives from the nasal region [2, 22–26]. The presence of small amounts of NO in the lower airways has been elegantly proven in tracheotomized and intubated patients [2, 22, 25]. During spontaneous breathing, the detection of NO derived from the lower airways is hampered by variable admixture of nasal NO into the respiratory gas depending, for example, on the position of the soft palate and the presence of a nose clip [26]. In a previous study comparing healthy and asthmatic children [5], a positive correlation between oral and nasal NO concentrations had indicated incomplete separation of the upper and lower airway NO fractions. In the present study, a modified experimental setup with optimized separation of pulmonary and nasal NO [27] was used and endogenous NO release studied in relation to recent clinical symptoms taking into account regular inhalation of glucocorticosteroids.
Patients and methods

Thirty-six children (18 female) between the age of 5.5 and 10.3 yrs (median age 8.1 yrs) were entered into the study after consent had been obtained from the local committee on research in human subjects and from the parents. Twenty-five children (median age 8.3 yrs) suffering from bronchial asthma as defined by the International Consensus Report [28] were recruited from the files of the asthma clinic at Luèbeck University Childrens’ Hospital (n=21) or via cooperation with local community paediatricians (n=4). All asthmatic children had had a total serum immunoglobulin (Ig)E \( > 100 \, \text{kU} \cdot \text{L}^{-1} \) in the past and 13 had a positive family history of atopic disease in first degree relatives. The diagnosis of asthma had been established at least 12 months before the study. The children were suffering from frequent episodic or persistent asthma with at least 12 months before the study. The children 13 had a positive family history of atopic disease in first degree relatives. The diagnosis of asthma had been established at least 12 months before the study. The children were suffering from frequent episodic or persistent asthma using current definitions [29]. Eleven children (median age 8 yrs) were healthy control subjects with no history of asthma, atopic dermatitis or atopic rhinitis and without bronchial asthma in first degree relatives. They were not receiving any medication. One child in the asthmatic group and two children in the control group suffered from mild rhinitis on the day of the examination and subclassified by regular inhaled steroid medication had been administered in standard doses according to clinical severity and are summarized in table 1.

Table 1. – Patient groups* and antiasthmatic treatment

<table>
<thead>
<tr>
<th>Symptom-free asthma</th>
<th>Symptomatic asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Steroids</td>
</tr>
<tr>
<td>Patients n</td>
<td>6</td>
</tr>
<tr>
<td>Disodium chromoglycate n</td>
<td>6</td>
</tr>
<tr>
<td>Short-acting ( \beta )-agonists n</td>
<td>6</td>
</tr>
<tr>
<td>Oral theophylline n</td>
<td>2</td>
</tr>
</tbody>
</table>

*: There were also 11 healthy control subjects.

All asthmatic children and their parents were specifically asked about the occurrence of dry cough at night or on exertion, wheezing, and breathlessness at rest or during exercise. The children were then classified by the presence or absence of any of those symptoms indicative of bronchial obstruction during the 2 weeks preceding the day of the investigation and subclassified by regular inhalation of glucocorticosteroids (table 1). The latter (budesonide aerosol 200–400 \( \mu \text{g} \cdot \text{day}^{-1} \)) had been applied for at least 4 weeks prior to the study. Other antiasthmatic medication had been administered in standard doses according to clinical severity and are summarized in table 1.

NO from the lower respiratory tract was measured in mixed exhaled gas at steady state conditions during tidal breathing. To prevent admixture of nasally produced NO into the orally exhaled gas, nasal gas was removed continuously. This was performed using suction applied via tightly fitted nasal masks (Respironics, Pittsburgh, PA, USA). In the nose, the resulting gas flow was directed from the pharynx through the open velum and through the nasal cavity. Thus, the tidal breathing method recommended by the European Respiratory Society [30] was modified by the additional maintenance of a continuous nasal suction. A fixed succional flow rate of 1.3 L-min\(^{-1}\) was achieved by the use of a pump in combination with a mass flow controller. The experimental setup is illustrated in figure 1.

Fig. 1. – Schematic illustration of NO measurement in orally exhaled gas during continued nasal suction. \( \rightarrow \): direction of gas flow. During the measurement of nasal NO the nasal mask was disconnected from the pump and directly connected to the chemiluminescence analyser sampling at the same succional flow (1.3 L-min\(^{-1}\)).
This is permissible because NO concentrations were determined in mixed exhaled gas.

Nasal NO was sampled using a modification of the setup shown in figure 1. The sampling port of the chemiluminescence analyser was directly connected to the nasal mask. Nasal NO excretion rates were determined by multiplication of mean nasal NO concentrations (averaged over 90 s) with the suctional flow rate of the analyser (1.3 L·min⁻¹).

The effect of nasal aspiration on measurements in orally exhaled gas was formally studied in four healthy children by comparing results from breathing during nasal suction with those while bearing a nose clamp. Nasal aspiration decreased the NO concentration in orally exhaled gas from 7.8±0.9 ppb while wearing a nose clamp to 2.7±0.2 ppb.

The repeatability of NO measurements in orally exhaled gas during nasal suction was evaluated as proposed by Azzolin et al. [31] and Bland and Altman [32]. For this purpose, two measurements taken on the same day in 10 children were compared. The mean difference of NO measurements in orally exhaled gas (2nd - 1st measurement) was 0.27±0.11 ppb (mean±SEM, NS). The coefficient of repeatability [32] was 0.69 ppb. Greater than 95% of results from breathing during nasal suction were statistically similar to those obtained by Azzolin et al. [31] in healthy children using different methodology.

Lung function was tested plethysmographically (Jäger) using standard normal values for children [33]. As markers of obstructive pulmonary function impairment resistance, forced expiratory volume in one second (FEV1) and maximum expiratory flow at 25% of vital capacity (MEF25) were retrieved for analysis.

For statistical comparison of the groups, Kruskal–Wallis test with Tukey–Kramer post hoc analysis for multiple comparisons and Mann–Whitney U-test with Bonferroni correction were applied (two-tailed testing). Spearman’s rank correlation was applied to test for correlations. Statistical significance was accepted at p-values ≤0.05. All results are given in mean±SEM.

---

**Results**

Orally exhaled NO concentrations during maintained nasal suction were 2.5±0.3 versus 5.8±0.8 ppb (mean±SEM, NS) and the corresponding excretion rates were 18.6±6.4 versus 45.6±6.4 nL·min⁻¹ (p<0.01) in the groups of healthy and asthmatic children, respectively. Mean expiratory flow in healthy control subjects was 190.0±12.5 mL·s⁻¹ and not significantly different in asthmatic children. Nasal NO concentration was 152.8±12.7 ppb and the corresponding excretion rate 198.7±10.1 nL·min⁻¹ in healthy control subjects, both of which were not significantly different in asthmatic children (185.2±13.8 ppb and 240.7±17.9 nL·min⁻¹, respectively).

Children with clinical symptoms during the preceding two weeks had significantly higher orally exhaled NO concentrations and excretion rates than symptom-free children with asthma or healthy control subjects (Kruskal–Wallis test, Tukey–Kramer post hoc analysis, p<0.01; table 2). Lung function parameters did not differ significantly between symptom-free and asthmatic children.

---

**Table 2.** NO concentrations, excretion rates and pulmonary function parameters in relation to clinical symptoms during the preceding two weeks

<table>
<thead>
<tr>
<th></th>
<th>Healthy control subjects</th>
<th>Symptom-free asthma</th>
<th>Symptomatic asthma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=11)</td>
<td>(n=12)</td>
<td>(n=13)</td>
</tr>
<tr>
<td><strong>Orally exhaled NO</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>concentration ppb</td>
<td>2.5±0.3</td>
<td>3.2±0.9</td>
<td>8.3±0.8**</td>
</tr>
<tr>
<td><strong>Excretion rate in orally exhaled gas nL·min⁻¹</strong></td>
<td>18.6±3.3</td>
<td>26.6±3.5</td>
<td>63.1±9.0**</td>
</tr>
<tr>
<td><strong>Nasal NO concentration ppb</strong></td>
<td>152.8±12.7</td>
<td>199.2±21.1</td>
<td>172.3±18</td>
</tr>
<tr>
<td><strong>Nasal excretion rate nL·min⁻¹</strong></td>
<td>198.7±16.5</td>
<td>259.0±27.4</td>
<td>224.0±23.5</td>
</tr>
<tr>
<td><strong>Minute ventilation L·min⁻¹</strong></td>
<td>7.6±0.5</td>
<td>9.2±0.7</td>
<td>7.3±0.5</td>
</tr>
<tr>
<td><strong>Resistance % pred</strong></td>
<td>124±8</td>
<td>168±21</td>
<td>156±17</td>
</tr>
<tr>
<td><strong>FEV1 % pred</strong></td>
<td>106±2</td>
<td>105±3</td>
<td>103±4</td>
</tr>
<tr>
<td><strong>MEF25 % pred</strong></td>
<td>95±4</td>
<td>74±11</td>
<td>69±7</td>
</tr>
</tbody>
</table>

Data are presented as mean±SEM. FEV1: forced expiratory volume in one second; MEF25: maximum expiratory flow at 25% of vital capacity. **: p<0.01.

---

**Fig. 2.** NO excretion rates (mean±SEM) in orally exhaled gas of asthmatic children and healthy control subjects (control). *: p<0.05; **: p<0.01, in comparison with healthy control subjects.

---

with asthma (table 2). There was no correlation between NO levels measured in orally expired gas and in nasally aspirated gas and no correlation of either of these with age or markers of obstructive pulmonary function impairment.

Significantly elevated orally exhaled NO concentrations in recently symptomatic children were found in both steroid-naïve (7.5±0.9 ppb, p<0.01) and steroid-treated (9.5±1.5 ppb, p<0.05) subjects in comparison with healthy control subjects. Likewise, NO excretions in those children were significantly higher (52.8±8.5 nL·min⁻¹, p<0.01 and 79.0±17.9 nL·min⁻¹, p<0.05, respectively, fig. 2) than in healthy control subjects. The highest exhaled NO concentrations and excretion rates were found in those children who despite glucocorticoid treatment had experienced clinical symptoms during the last two weeks before the study.
EXHALED NO IN CHILDHOOD ASTHMA

Discussion

The present data provide evidence for a significantly higher exhaled NO concentration and excretion rate from the lower airways in symptomatic children with atopic asthma compared with symptom-free children and with healthy control subjects irrespective of glucocorticosteroid treatment. In addition, the data suggest that measurement of NO in orally exhaled gas may be more sensitive to detect deterioration of asthmatic control than standard pulmonary function testing, which revealed no significant differences between the groups.

The application of nasal suction to prevent admixture of nasally produced NO into fractions from the lower airways allowed separate measurements of pulmonary and nasal portions of endogenous NO production. Examining adult lungs in healthy intubated patients, Schedin et al. [25] found 1.3±0.2 ppb (mean±SEM) NO in tracheal gas, which is similar to the present finding of 2.5±0.3 ppb NO in orally exhaled gas of healthy children. Moreover, they calculated NO release to be 0.2–0.8 nmol-min⁻¹ [25] using the general gas law, the analogous calculation from the present data yields 0.74±0.13 nmol-min⁻¹. Using bronchoscopic tracheal peak measurements during 15–20 s breath-holds, Kharitonov et al. [9] and Massaro et al. [10] found 4.1±1 and 8.2±1.9 ppb in healthy patients versus 39±12 and 32.8±6.6 ppb (mean±SEM) in patients with asthma, respectively. These values are higher than the present values because breath-holding will lead to an accumulation of continuously produced NO. In conclusion, NO rates in orally exhaled gas obtained by the present sampling technique can be considered as the upper limit of the NO production in the lower airways. In contrast to the authors' previous work [5], the present data show no correlation between upper and lower airway NO measurements indicating successful removal of nasal NO from the respiratory gas. The current sampling technique was well tolerated by all participating children.

Recent studies [34, 35] have suggested a dependence of lower airway NO excretion on expiratory flow rate. Hoggman et al. [35] reported a 25% increase of NO excretion rate at 300 mL·s⁻¹ compared to 50 mL·s⁻¹ using flow restrictors to assure steadiness of the expiratory flow rate. In the present measurements the expiratory flow rate was clearly not constant, but the values for minute ventilation and the corresponding mean expiratory flow rates during NO measurement as well as the pulmonary function parameters in the different groups of asthmatic children were not statistically different from healthy control subjects. It is thus reasonable to assume that the variation of the expiratory flow rate had comparable effects on the NO excretion rates in all groups of children.

Therefore, influences on the significant differences of NO excretion rates between the groups are expected to be minor. This judgement is supported by the fact that Alving et al. [2] described an increased amount of NO in the exhaled gas of asthmatics during tidal breathing even in the presence of confounding nasally produced NO.

The magnitude of NO concentrations in orally exhaled gas of asthmatic children reported in this study defines lower airway NO levels occurring during spontaneous oral breathing more precisely than previous work in adults [2–4, 9, 10] and in children [5–8]. In addition to previous work regarding asthmatic patients in general, the present data demonstrate a difference between symptomatic and symptom-free asthmatic children. As it is shown that continuous nasal aspiration lowers NO concentrations in orally exhaled gas by preventing nasal contamination, it is speculated that exhaled NO measurement during nasal suction may be an alternative to sampling methods which require maintenance of velum closure.

The phenomenon of low orally exhaled NO concentrations and excretion rates in asthmatic subjects treated with glucocorticosteroids has previously been found in adult patients [4]. Moreover, longitudinal studies have shown a decrease of orally exhaled NO after institution of anti-inflammatory therapy with inhaled glucocorticosteroids [8, 10, 20, 21], and dose dependency of this suppressive effect [36]. The present data demonstrate that the NO concentrations in orally exhaled gas of successfully treated asthmatic children are within the range of healthy control subjects irrespective of glucocorticosteroid medication. Moreover, recent symptoms of bronchial obstruction are linked to increased NO concentrations in orally exhaled gas even if steroids are part of the medication. Several reasons may explain why some children had very high NO concentrations in orally exhaled gas in spite of glucocorticosteroid treatment. Poor inhalation technique, non-compliance with the inhalation regimen, inadequate glucocorticosteroid dosage or overwhelming inflammatory activity may have played a role.

Use of short acting b-agonists was more prevalent in the group of asymptomatic patients who had lower NO concentrations compared with recently symptomatic patients. Inhalation of b-agonists has, on the other hand, been linked to elevations of exhaled NO concentrations in adult asthmatic patients [37, 38]. Thus, the slightly more frequent use of short-acting b-agonists in the group of symptom-free children (table 1) is unlikely to explain the lower NO concentrations in orally exhaled gas occurring in this group.

Similar to others [6, 7], this study found no significant difference of nasally exhaled NO between healthy children and those with asthma in spite of different experimental setups. This is supported by the recent demonstration of a "fundamental difference" between the regulation of NO production in the lower airways and in the nose, most of which takes place in the paranasal sinuses [7, 23, 24]. In contrast to bronchial epithelium, the mucosa in the paranasal sinuses shows constitutive expression of an inducible-like NO synthase which does not seem to be influenced by treatment with glucocorticosteroids. The reason for elevated nasal NO concentrations in adult asthmatic patients as found by Kharitonov et al. [9] is therefore unexplained at present.

Recently, several authors have looked at the relationship between exhaled NO levels and asthma severity. Ten Hacken et al. [39] found no correlation between NO concentration in mixed exhaled air and objective parameters of asthma severity (FEV₁, provocative concentration of methacholine and adenosine causing a 20% fall in FEV₁, total eosinophil count, total serum IgE). On the other hand, Kharitonov and coworkers [20, 36] found a decrease of nocturnal symptoms, diurnal peak expiratory flow variability and airway responsiveness to methacholine with decreasing oral exhaled NO concentrations in adults. There was no change of FEV₁ in their study, which parallels the present finding of insignificant differences of
pulmonary function parameters between the study groups. The authors’ own previous finding of a weak negative correlation between FEV1 and oral exhaled NO concentration [5] could not be reproduced in the present study. Taylor et al. [40], who found no correlation between exhaled NO and airway responsiveness (functionally correlated with FEV1), suggest that the two indicate distinct inflammatory mechanisms. Pulmonary function tests alone may thus not allow definite conclusions about the severity of the asthmatic state.

The present finding of significantly higher exhaled NO values in symptomatic children compared with symptom-free children and healthy control subjects parallels the report of increasing nocturnal cough with increasing exhaled NO concentrations in adults [36]. Therefore, if substantiated in longitudinal studies involving larger numbers of patients, measurement of NO from the lower airways may offer a promising possibility to monitor effectiveness of antiasthmatic therapy even in young children, at least in addition to pulmonary function tests. However, its usefulness in clinical practice can only be assessed on the basis of further work studying confounding factors influencing its sensitivity and specificity.

Acknowledgements. The authors thank all children and their parents for their enthusiastic participation, C. Grywatz for pulmonary function testing, I. Dickau for correspondence with the families, E. de Bary, R. Höhne, S. Mahdi and A. Richter for referring some of the patients for the study, R. Mohnhaupt for providing the software for data retrieval, J.-U. Hagenah, Draegerwerk AG, Lübeck, Germany for stimulating discussions.

References